Enrolling by InvitationN/Apsilocybin

Salivary Oxytocin as a Biomarker of Psychedelic Treatment

Sponsored by University of Geneva, Switzerland

NCT ID
NCT07345858
Target Enrollment
80 participants
Start Date
2026-01-05
Est. Completion
2026-10-30

About This Study

This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.

Conditions Studied

Major Depressive Disorder (MDD)

Eligibility

Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Age \>=18 years-old
* MDD defined by DSM-V criteria, and resistant to treatment
* Ongoing classical psychotherapeutic treatment
* Agreement to discontinue necessary psychotropic medications (some classes of anti-depressants are allowed with no need to taper off).

Exclusion Criteria:

* Psychotic or bipolar disorder
* High suicidal risk
* Severe cardiovascular, hepatic or neurological (affecting the central nervous system) disorders
* Pregnancy or breastfeeding.

Study Locations (1)

Geneva University Hospitals
Geneva, Switzerland

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source

Salivary Oxytocin as a Biomarker of Psychedelic Treatment | Huxley